Regeneron Pharmaceuticals, Inc.
"Sector" = median of Healthcare across 84 companies
About Regeneron Pharmaceuticals, Inc.
AI-generatedRegeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious medical conditions. Founded in 1988 and headquartered in Tarrytown, New York, it is known for its expertise in genetics and protein engineering. Key products include Eylea (aflibercept) for eye diseases, Dupixent (dupilumab) for inflammatory conditions (partnered with Sanofi), and Libtayo (cemiplimab) for cancer. The company also has a pipeline in areas such as genetic medicines, oncology, and immunology.
Regeneron generates revenue primarily from product sales and collaboration agreements. Its top-selling drug is Eylea, used for wet age-related macular degeneration and diabetic eye disease, which contributes a significant portion of sales. Dupixent, co-developed with Sanofi, is another major revenue driver for allergic and inflammatory diseases. The company also earns royalties and milestone payments from partnerships. It invests heavily in R&D, with a focus on innovative therapies and proprietary technologies like VelociSuite.
The biotechnology industry is highly competitive, with companies like Amgen, AbbVie, and Roche. Regeneron differentiates itself through its genetics-based drug discovery platform and strong pipeline. It holds a leading position in ophthalmology with Eylea, though it faces biosimilar competition. In immunology, Dupixent has multiple approved indications and continues to expand. The company's financials show high gross margins (85.35%) and solid profitability, but earnings declined 10% year-over-year, partly due to increased R&D spending.
Regeneron's customers are primarily patients and healthcare providers, including physicians, hospitals, and clinics. Its medicines target chronic and serious diseases such as macular degeneration, asthma, atopic dermatitis, and certain cancers. Geographically, the US is the largest market, accounting for the majority of sales, followed by Europe and Japan. The company also has a growing presence in emerging markets through partnerships and direct operations.
An auto-generated descriptive profile based on company data, for informational purposes only.
Regeneron Pharmaceuticals (REGN) shares edged down 0.33% to $676.69, reflecting continued pressure from disappointing trial results reported in Q2. The company secured FDA Priority Review and EMA acceptance for cemdisiran, a potential new therapy, which may offset some negative sentiment. Meanwhile, the broader biotech sector is shifting focus back to fundamentals, and Regeneron is mentioned among early participants in the FDA's fast-track facility scheme, signaling regulatory engagement.
- •Regeneron stock fell 0.33% to $676.69 amid lingering disappointment from Q2 trial results.
- •FDA granted Priority Review and EMA accepted filing for cemdisiran, a potential new therapy.
- •Regeneron named among early participants in FDA's fast-track facility scheme.
- •Biotech sector expected to shift focus to fundamentals in H2, per Morgan Stanley.
Financial highlights
Latest saved period: March 2026 · 2026-03-31
Dividend history
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Feb 20, 2026 | $0.94 | Mar 5, 2026 | Quarterly |
| Nov 20, 2025 | $0.88 | Dec 5, 2025 | Quarterly |
| Aug 18, 2025 | $0.88 | Sep 3, 2025 | Quarterly |
| May 20, 2025 | $0.88 | Jun 6, 2025 | Quarterly |
| Feb 20, 2025 | $0.88 | Mar 20, 2025 | Other |
Revenue
↑ 84.7%Net Income
↓ 19.0%Free Cash Flow
↓ 1.7%Diluted EPS
↓ 7.2%Regeneron Pharmaceuticals, Inc. (REGN) analysis
Wrqti brings Regeneron Pharmaceuticals, Inc. data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Stocks related to Regeneron Pharmaceuticals, Inc.
Companies in the Healthcare sector you can compare with Regeneron Pharmaceuticals, Inc.: